#Samsung Biologics
Total 2 articles
PoliticsEN
Lilly Bets on Korea's Biotech Ambitions
Samsung Biologics and Eli Lilly will co-establish a Lilly Gateway Labs site in Songdo, Incheon by 2027. What does this mean for Korea's biotech ecosystem and global pharma strategy?
EconomyEN
Samsung Biologics Buys GSK's U.S. Facility for $280M in Major North American Push
Samsung Biologics is acquiring a U.S. drug production facility from GSK for $280 million. The deal marks a significant expansion into the North American CDMO market, aiming to secure local production capacity.
